Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2RTEbBD
via IFTTT